R 547

Drug Profile

R 547

Alternative Names: R547

Latest Information Update: 08 Aug 2011

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 04 Mar 2010 No development reported - Phase-I for Solid tumours in USA (IV)
  • 04 Mar 2010 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 01 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top